Edith T Zemanick, Mscs

List of Publications by Year
in descending order

72	2,905	201674 27	175258 52
papers	citations	h-index	g-index

76	76	76	3376
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cardiovascular complications in cystic fibrosis: A review of the literature. Journal of Cystic Fibrosis, 2022, 21, 18-25.	0.7	25
2	Clinical characteristics of people with cystic fibrosis and frequent fungal infection. Pediatric Pulmonology, 2022, 57, 152-161.	2.0	8
3	Microbiome in Cystic Fibrosis. Respiratory Medicine, 2022, , 147-177.	0.1	2
4	Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. Journal of Cystic Fibrosis, 2021, 20, 965-971.	0.7	11
5	Long-term safety and efficacy of tezacaftorâ€“ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respiratory Medicine,the, 2021, 9, 733-746.	10.7	33
6	Change in circulating proteins during treatment of pulmonary exacerbation in patients with cystic fibrosis. Health Science Reports, 2021, 4, e246.	1.5	3
7	Development of a National Academic Boot Camp to Improve Fellowship Readiness. ATS Scholar, 2021, 2, 49-65.	1.3	2
8	Detection of bacterial pathogens using home oropharyngeal swab collection in children with cystic fibrosis. Pediatric Pulmonology, 2021, 56, 2043-2047.	2.0	12
9	Importance of beta-lactam pharmacokinetics and pharmacodynamics on the recovery of microbial diversity in the airway of persons with cystic fibrosis. Journal of Investigative Medicine, 2021, 69, 1350-1359.	1.6	6
10	Fungal Infection and Inflammation in Cystic Fibrosis. Pathogens, 2021, 10, 618.	2.8	7
11	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1522-1532.	5.6	146
12	Impact of Anaerobic Antibacterial Spectrum on Cystic Fibrosis Airway Microbiome Diversity and Pulmonary Function. Pediatric Infectious Disease Journal, 2021, Publish Ahead of Print, 962-968.	2.0	4
13	Influence of Acid Blockade on the Aerodigestive Tract Microbiome in Children With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 520-527.	1.8	3
14	Bacterial Signatures of Paediatric Respiratory Disease: An Individual Participant Data Meta-Analysis. Frontiers in Microbiology, 2021, 12, 711134.	3.5	5
15	Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure. Journal of Cystic Fibrosis, 2020, 19, 114-118.	0.7	7
16	Dissociation of systemic and mucosal autoimmunity in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 196-202.	0.7	17
17	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24
18	Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation. Annals of the American Thoracic Society, 2020, 17, 212-220.	3.2	113

#	Article	IF	Citations
19	Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis. Pediatric Pulmonology, 2020, 55, 521-525.	2.0	8
20	Airway microbial diversity is decreased in young children with cystic fibrosis compared to healthy controls but improved with CFTR modulation. Heliyon, 2020, 6, e04104.	3.2	11
21	Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Pediatric Pulmonology, 2020, 55, 3400-3406.	2.0	8
22	Nanodiagnostics to monitor biofilm oxygen metabolism for antibiotic susceptibility testing. Analyst, The, 2020, 145, 3996-4003.	3.5	5
23	Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor. Journal of Cystic Fibrosis, 2019, 18, 144-149.	0.7	36
24	Entering the era of highly effective CFTR modulator therapy. Lancet, The, 2019, 394, 1886-1888.	13.7	6
25	Luminescent Nanosensors for Ratiometric Monitoring of Three-Dimensional Oxygen Gradients in Laboratory and Clinical Pseudomonas aeruginosa Biofilms. Applied and Environmental Microbiology, 2019, 85, .	3.1	18
26	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	5.8	62
27	Unraveling the CFTR Functionâ€“Phenotype Connection for Precision Treatment in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1053-1054.	5.6	3
28	Changes in microbiome diversity following beta-lactam antibiotic treatment are associated with therapeutic versus subtherapeutic antibiotic exposure in cystic fibrosis. Scientific Reports, 2019, 9, 2534.	3.3	17
29	Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2019, 25, 636-645.	2.6	5
30	Bacterial Community Variability: Outliers May Be Leading Us Astray. Annals of the American Thoracic Society, 2019, 16, 1499-1501.	3.2	3
31	Novel Application of Aptamer Proteomic Analysis in Cystic Fibrosis Bronchoalveolar Lavage Fluid. Proteomics - Clinical Applications, 2019, 13, e1800085.	1.6	12
32	Highlights from the 2017 North American Cystic Fibrosis Conference. Pediatric Pulmonology, 2018, 53, 979-986.	2.0	7
33	Volatile molecules from bronchoalveolar lavage fluid can â€˜rule-inâ€™ Pseudomonas aeruginosa and â€˜rule-outâ€™ Staphylococcus aureus infections in cystic fibrosis patients. Scientific Reports, 2018, 8, 826.	3.3	44
34	Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 760-768.	0.7	13
35	On the Use of Diversity Measures in Longitudinal Sequencing Studies of Microbial Communities. Frontiers in Microbiology, 2018, 9, 1037.	3.5	135
36	Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1177-1187.	5.6	75

#	Article	IF	Citations
37	Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. Journal of Cystic Fibrosis, 2017, 16, 371-379.	0.7	46
38	Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax, 2017, 72, 318-326.	5.6	46
39	Lessons from the lower airway microbiome in early CF. Thorax, 2017, 72, 1063-1064.	5.6	3
40	Highlights from the 2016 North American Cystic Fibrosis Conference. Pediatric Pulmonology, 2017, 52, 1103-1110.	2.0	10
41	Airway microbiota across age and disease spectrum in cystic fibrosis. European Respiratory Journal, 2017, 50, 1700832.	6.7	193
42	Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis. BMC Pulmonary Medicine, 2017, 17, 188.	2.0	6
43	Impact of enzymatic digestion on bacterial community composition in CF airway samples. PeerJ, 2017, 5, e3362.	2.0	6
44	Airway Microbiota in Bronchoalveolar Lavage Fluid from Clinically Well Infants with Cystic Fibrosis. PLoS ONE, 2016, 11, e0167649.	2.5	53
45	Cystic fibrosis. Current Opinion in Pediatrics, 2016, 28, 312-317.	2.0	44
46	Alterations of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis. Cystic Fibrosis Transmembrane Conductance Regulator and Antibiotic Effects. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 473-474.	5.6	1
47	Cystic Fibrosis. Pediatric Clinics of North America, 2016, 63, 617-636.	1.8	38
48	Assessing the Airway Microbiota in Cystic Fibrosis. Clinical Microbiology Newsletter, 2016, 38, 179-184.	0.7	2
49	Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. Pediatrics, 2016, 137, .	2.1	140
50	Molecular Identification of Staphylococcus aureus in Airway Samples from Children with Cystic Fibrosis. PLoS ONE, 2016, 11, e0147643.	2.5	15
51	Cholesteryl Esters Are Elevated in the Lipid Fraction of Bronchoalveolar Lavage Fluid Collected from Pediatric Cystic Fibrosis Patients. PLoS ONE, 2015, 10, e0125326.	2.5	9
52	Editorial Commentary:Pseudomonas aeruginosaEradication: How Do We Measure Success?. Clinical Infectious Diseases, 2015, 61, 716-718.	5.8	3
53	Sputum induction improves detection of pathogens in children with cystic fibrosis. Pediatric Pulmonology, 2015, 50, 638-646.	2.0	29
54	Assessment of Airway Microbiota and Inflammation in Cystic Fibrosis Using Multiple Sampling Methods. Annals of the American Thoracic Society, 2015, 12, 221-229.	3.2	128

#	Article	IF	Citations
55	Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatric Pulmonology, 2015, 50, 42-48.	2.0	59
56	Intestinal Lesions Are Associated with Altered Intestinal Microbiome and Are More Frequent in Children and Young Adults with Cystic Fibrosis and Cirrhosis. PLoS ONE, 2015, 10, e0116967.	2.5	78
57	Narrowing in on Early Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1082-1084.	5.6	5
58	Advances in the Diagnosis and Treatment of Cystic Fibrosis. Advances in Pediatrics, 2014, 61, 225-243.	1.4	13
59	Cystic Fibrosis Transmembrane Conductance Regulator andPseudomonas. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 763-765.	5.6	3
60	Microbes in Bronchiectasis: The Forest or the Trees?. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1044-1045.	5.6	10
61	Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations. PLoS ONE, 2013, 8, e62917.	2.5	155
62	Newborn screening for cystic fibrosis. Current Opinion in Pediatrics, 2012, 24, 329-335.	2.0	69
63	Sputum Biomarkers of Inflammation and Lung Function Decline in Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 857-865.	5.6	207
64	Chronic cough. , 2011, , 400-403.		0
65	Clinical Value Of Sputum Induction To Diagnose Infection In Cystic Fibrosis. , 2011, , .		0
66	Anaerobic Bacteria As Biomarkers Of Lung Function Decline In Cystic Fibrosis. , 2011, , .		0
67	The airway microbiome in cystic fibrosis and implications for treatment. Current Opinion in Pediatrics, 2011, 23, 319-324.	2.0	89
68	Evaluation of cough and pulmonary disorders. , 2011, , 393-395.		0
69	Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. Pediatric Pulmonology, 2010, 45, 569-577.	2.0	41
70	Reliability of Quantitative Real-Time PCR for Bacterial Detection in Cystic Fibrosis Airway Specimens. PLoS ONE, 2010, 5, e15101.	2.5	71
71	Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy. Journal of Cystic Fibrosis, 2010, 9, 1-16.	0.7	93
72	Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20529-20533.	7.1	339